SRB
Steve R. Bailey Portfolio
Invests via Frazier Life Sciences Management LP | Managed by James W. Brush, M.D.
Invests via Frazier Life Sciences Management LP
Managed by James W. Brush, M.D.
Automatically Tracked
Steve R. Bailey Profile
Steve R. Bailey has carved a significant niche within the financial services sector, establishing himself as a seasoned investor-operator with a robust background in corporate finance and venture capital. His diverse experience spans various industries, including technology and healthcare, where he has played key roles in scaling innovative startups into market leaders. Known for his strategic acumen and hands-on approach to growth, he effectively bridges the gap between entrepreneurial ambition and operational execution. His leadership not only reflects an understanding of dynamic market demands but also positions him as an influential figure capable of navigating complex investment landscapes.
Steve R. Bailey has carved a significant niche within the financial services sector, establishing himself as a seasoned investor-operator with a robust background in corporate finance and venture capital. His diverse experience spans various industries, including technology and healthcare, where he has played key roles in scaling innovative startups into market leaders. Known for his strategic acumen and hands-on approach to growth, he effectively bridges the gap between entrepreneurial ambition and operational execution. His leadership not only reflects an understanding of dynamic market demands but also positions him as an influential figure capable of navigating complex investment landscapes.
Investment Philosophy & Strategy
Analyzing emerging market trends reveals significant investment opportunities in innovative sectors. Steve R. Bailey leverages his extensive operational expertise to identify and support companies that exhibit strong growth potential and scalable business models. His approach often combines hands-on mentorship with strategic capital deployment, emphasizing long-term value creation over short-term gains. Through meticulous evaluation of entrepreneurial ventures, he focuses on fostering resilience and competitive advantage among startups within the technology and healthcare industries. This blend of financial insight and operational rigor positions him uniquely to not only drive successful investments but also contribute positively to the broader economic landscape.
Analyzing emerging market trends reveals significant investment opportunities in innovative sectors. Steve R. Bailey leverages his extensive operational expertise to identify and support companies that exhibit strong growth potential and scalable business models. His approach often combines hands-on mentorship with strategic capital deployment, emphasizing long-term value creation over short-term gains. Through meticulous evaluation of entrepreneurial ventures, he focuses on fostering resilience and competitive advantage among startups within the technology and healthcare industries. This blend of financial insight and operational rigor positions him uniquely to not only drive successful investments but also contribute positively to the broader economic landscape.
Disclaimer: This Portfolio is derived from and computed based on publicly available data from SEC filings.
Gain and growth charts are calculated per selected timeframe:
526.22%
Gain +36.24%
Monthly
3.88%
Yearly
57.96%
Drawdown
75.38%
$4.98B
Equity
Holdings
$4.98B
Investment
$2.05B
$3.38B
Profit +$582.74M
Realized
$448.14M
Unrealized
$2.93B
Dividends
$0
Goals
Avg. 100% completed goals
Yearly
Gain > 5% 2026
Yearly
Gain < 20% 2026
Today
Compared To Yesterday
Gain
36.24%
Profit
$582.74M
Win %
86%
This Week
Compared To Last Week
Gain
13.37%
Profit
$587.8M
Win %
86%
This Month
Compared to last month
Gain
13.42%
Profit
$589.92M
Win %
86%
This Year
Compared to last year
Gain
18.79%
Profit
$825.79M
Win %
86%
AGIO Agios Pharmaceuticals Inc.
+17.7%
+$8.32M 
TRVI Trevi Therapeutics Inc.
+8.63%
+$15.41M 
BCRX BioCryst Pharmaceuticals Inc.
+8.06%
+$3.29M 
MBX MBX Biosciences, Inc.
+7.45%
+$28.6M 
NAMSW NewAmsterdam Pharma Company N.V.
+6.19%
+$725,482.85 
ARQT Arcutis Biotherapeutics Inc.
+6.14%
+$15.8M 
NAMS NewAmsterdam Pharma Co. N.V.
+5.99%
+$35.41M 
MIRM Mirum Pharmaceuticals Inc.
+5.25%
+$49.15M 
TARS Tarsus Pharmaceuticals Inc.
+5.22%
+$2.55M 
GLUE Monte Rosa Therapeutics, Inc.
+4.95%
+$1.15M 
IMCR Immunocore Holdings plc American Depositary Receipt
+4.57%
+$707,781.72 
DYN Dyne Therapeutics Inc.
+4.33%
+$3.12M 
LXEO Lexeo Therapeutics Inc.
+4.13%
+$840,697.75 
PVLA Pavella Therapeutics Inc.
+3.84%
+$4.76M 
IRON Disc Medicine Inc.
+3.57%
+$3.73M 
ALLO Allogene Therapeutics Inc.
+2.87%
+$227,800.08 
ACRS Aclaris Therapeutics, Inc.
+2.37%
+$640,298.62 
ACAD Acadia Pharmaceuticals Inc.
+1.67%
+$618,425.14 
MAZE Maze Therapeutics Inc.
+1.51%
+$2.24M 
PHAT Phathom Pharmaceuticals Inc.
+1.49%
+$2.12M 
ZLAB Zai Lab Ltd.
+1.42%
+$513,626.4 
RVMD Revolution Medicines Inc.
+0.25%
+$317,572.42 
BBIO BridgeBio Pharma, Inc.
+0.21%
+$551,702.24 
SVRA Savara Inc.
+0.16%
+$97,208.52 
ALKS Alkermes plc
+0.14%
+$56,051.76 
KALV KalVista Pharmaceuticals Inc.
0%
$0 
VOR Vor Biopharma Inc.
0%
$0 
ERAS Erasca, Inc.
-2.6%
-$12.09M 
VALN Valneva SE
-2.59%
-$320,833.24 
IBIO iBio, Inc.
-1.85%
-$58,604.01 
KRYS Krystal Biotech Inc.
-1.62%
-$2.93M 
XLO Xilio Therapeutics, Inc.
-1.38%
-$54,925.65 
AUTL Autolus Therapeutics plc American Depositary Receipt
-1.23%
-$88,958.2 
MNKD MannKind Corporation
-1.17%
-$295,000 
AURA Aura Biosciences Inc.
-0.85%
-$306,000 
EOLS Evolus Inc.
-0.71%
-$131,533.25 
ASND Ascendis Pharma A/S
-0.35%
-$126,666.35 
CYTK Cytokinetics, Incorporated
-0.01%
-$11,598.79 Events
Loading...
Dividends
Dividend Analysis
Loading...
No Data
| Trades 405 | Longs Won 238/405 58% | Profit Factor 9.43 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $32.74M |
| Average Win $15.89M | Best Trade (Jul 08) $379.13M | Sharpe Ratio 0 |
| Average Loss -$2.4M | Worst Trade (Sep 29) -$19.35M | Z-Score 4.54 (100%) |
| Commissions $0 | Avg. Trade Length 1y 6m 4d | Expectancy $8.35M |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | 0.03% |
| Consecutive Losing Trades | 2,075 | 1,867 | 1,660 | 1,452 | 1,245 | 1,037 | 830 | 622 | 415 | 207 |
Hover over the desired column for a detailed explanation.
Returns
Overall, MonthlyNo Data
Option values are updated at end of day.
No Data
No Data
Option values are updated at end of day.
No Data
No Data
No Data
No Data
